Developing targeted treatments for rare kidney diseases
Crescentic glomerulonephritis rapidly damages the kidney's filtering units and can lead to kidney failure, dialysis or transplantation. Existing treatments primarily suppress the immune response rather than act directly on the kidney, leaving a need for therapies that preserve renal function.
DETERA Therapeutics is developing DTR8 for crescentic glomerulonephritis. The drug candidate blocks HB-EGF, a growth factor involved in kidney cell proliferation, and is intended to preserve kidney function alongside existing immunosuppressive treatment.
What stands out about DETERA Therapeutics
Demonstrated DTR8 efficacy in a preclinical pig model, with non-toxicity results in preclinical testing.
Won the Ipsen Golden Ticket 2025, including incubation at BioLabs Hôtel-Dieu and scientific and strategic support.
Secured a Bpifrance grant to support development of its rare kidney disease therapies.
Built on co-founder Lyse Santoro's experience leading an international business unit at Ipsen.
Co-founded by Pierre-Louis Tharaux, a nephrologist and Inserm researcher who serves as chief medical officer.
Co-founded by Daniel Gillet, a toxin-engineering specialist who designed DTR8 and leads its scientific development.
Spun out of the CEA to develop kidney therapies originating in research by CEA-Joliot and Inserm.
Won an i-Lab 2026 innovation award for developing DTR8 to treat crescentic glomerulonephritis.
Received incubation at BioLabs Hôtel-Dieu through the Ipsen Golden Ticket 2025, including scientific and strategic support.
Backed by CEA Investissement and SATT Paris-Saclay as shareholders.
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.